Literature DB >> 29554420

Synthesis and Application of Hexamethyl-1,1'-spirobiindane-Based Phosphine-Oxazoline Ligands in Ni-Catalyzed Asymmetric Arylation of Cyclic Aldimines.

Weiye Sun1, Haorui Gu1, Xufeng Lin1.   

Abstract

With the vastly increasing applications of chiral phosphine-oxazoline (PHOX) hybrid ligands in various transition-metal-catalyzed reactions, novel PHOX ligands bearing innovative backbones are highly valuable and in great demand. This study describes the development of a new type of chiral PHOX ligands based on a hexamethyl-1,1'-spirobiindane scaffold and incorporating both a phosphine and an oxazoline moiety. The optimal ligand provided high yields and excellent enantioselectivities for the Ni-catalyzed asymmetric arylation of cyclic N-sulfonyl imines with arylboronic acids leading to chiral amines.

Entities:  

Year:  2018        PMID: 29554420     DOI: 10.1021/acs.joc.8b00422

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  4 in total

1.  Further Developments and Applications of Oxazoline-Containing Ligands in Asymmetric Catalysis.

Authors:  Robert Connon; Brendan Roche; Balaji V Rokade; Patrick J Guiry
Journal:  Chem Rev       Date:  2021-05-21       Impact factor: 60.622

2.  Enantioselective synthesis of α-amino ketones through palladium-catalyzed asymmetric arylation of α-keto imines.

Authors:  Wei Wen; Zhao-Pin Ai; Chang-Lin Yang; Chao-Xing Li; Zhu-Lian Wu; Tian Cai; Qi-Xiang Guo
Journal:  Chem Sci       Date:  2022-03-07       Impact factor: 9.825

3.  D-Fructose-based spiro-fused PHOX ligands: synthesis and application in enantioselective allylic alkylation.

Authors:  Michael R Imrich; Jochen Kraft; Cäcilia Maichle-Mössmer; Thomas Ziegler
Journal:  Beilstein J Org Chem       Date:  2018-08-08       Impact factor: 2.883

Review 4.  Focusing on the Catal. of the Pd- and Ni-Catalyzed Hirao Reactions.

Authors:  György Keglevich; Réka Henyecz; Zoltán Mucsi
Journal:  Molecules       Date:  2020-08-26       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.